By: Adam Feuerstein | 01/29/14 - 07:21 AM EST
Biogen Idec (BIIB) reported better-than-expected sales for its multiple sclerosis drug Tecfidera in the fourth quarter and issued a mixed outlook for 2014 financial guidance.
The company's projects 2014 revenue growth to be 22-25% vs. consensus of 21%, so slightly better than expected. Biogen's guidance implies 2014 total revenue in the range of $8.45 billion to $8.66 billion compared to current consensus of $8.35 billion.
On the bottom line, Biogen forecasts 2014 adjusted earnings per share in the range of $11 to $11.20, which is below the consensus of $11.63 per share. It looks like higher R&D costs in 2014 may be the reason for the weaker earnings guidance, according to analysts.
For the fourth quarter, Biogen reported adjusted earnings of $2.34 per share vs. $2.27 consensus. Revenue came in at $1.97 billion vs. $1.94 billion consensus.
Sales of Tecfidera in the fourth quarter totaled $398 million vs. $345 million consensus.
07/24/14 - 09:21 AM EDT
07/23/14 - 05:44 PM EDT
07/23/14 - 12:26 PM EDT
07/23/14 - 10:17 AM EDT
07/22/14 - 12:12 PM EDT
07/24/14 - 08:03 AM EDT
07/24/14 - 07:25 AM EDT
07/23/14 - 11:39 AM EDT
07/23/14 - 10:05 AM EDT
07/22/14 - 12:00 PM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.